{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:22:53Z","timestamp":1790504573597,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.critrevonc.2016.07.001","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T22:21:20Z","timestamp":1467757280000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome): Use in a community setting"],"prefix":"10.1016","volume":"106","author":[{"given":"Sunil A.","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2016.07.001_bib0005","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0015","series-title":"Cutaneous T-cell lymphoma: a dermatologist's perspective","author":"Aires","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0020","series-title":"Cancer facts & figs","author":"American Cancer Society","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0025","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0030","unstructured":"BELEODAQ (belinostat) [package insert]. Irvine, CA : Spectrum Pharmaceuticals, Inc. 2014."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0040","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0055","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0060","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0190-9622(98)70198-7","article-title":"Mycosis fungoides in young patients: clinical characteristics and outcome","volume":"38","author":"Crowley","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3945\/ajcn.112.053132","article-title":"Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies","volume":"98","author":"Del Gobbo","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0070","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1548-5315(11)70414-4","article-title":"Mycosis fungoides and Sezary syndrome: the burden of pruritus","volume":"7","author":"Demierre","year":"2010","journal-title":"Commun. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0080","first-page":"233","article-title":"Electrolyte disorders and arrhythmogenesis","volume":"18","author":"El-Sherif","year":"2011","journal-title":"Cardiol. J."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0085","unstructured":"FDA Drug Safety Communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron) 2014."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8575","article-title":"Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and\/or folliculotropic involvement","volume":"32","author":"Foss","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2016.07.001_bib0095","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomark Res."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0100","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.2680.2680","article-title":"Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin","volume":"118","author":"Godfrey","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and S\u00e9zary syndrome: a stage-based approach","volume":"6","author":"Horwitz","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0110","unstructured":"ISTODAX (romidepsin) [package insert]. Summit, NJ : Celgene Corporation, 2014."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patterns of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and S\u00e9zary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part II Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0130","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1634\/theoncologist.7-1-65","article-title":"The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern","volume":"7","author":"Keefe","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/icb.2011.100","article-title":"HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications","volume":"90","author":"Khan","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428194.2012.711829","article-title":"Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0150","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3109\/10428194.2015.1014360","article-title":"Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma","volume":"56","author":"Kim","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0155","article-title":"Responses to romidepsin in patients with relapsed\/refractory cutaneous T-cell lymphoma and dose modification: subanalysis of the pivotal phase 2 study","author":"Kim","year":"2016","journal-title":"T-Cell Lymphoma Forum"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2133.2005.06676.x","article-title":"Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and S\u00e9zary syndrome","volume":"153","author":"Klemke","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0165","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-Cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2016.07.001_bib0170","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3816\/CLC.2005.s.004","article-title":"Histone deacetylase inhibitors: emerging anticancer therapeutic agents?","volume":"7","author":"Kristeleit","year":"2005","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0175","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.hoc.2008.07.014","article-title":"Cutaneous T-cell lymphoma","volume":"22","author":"Lansigan","year":"2008","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0180","series-title":"Cutaneous T-cell lymphoma facts","author":"Leukemia and Lymphoma Society","year":"2016"},{"issue":"Suppl. 17570","key":"10.1016\/j.critrevonc.2016.07.001_bib0185","article-title":"Medical oncologists\u2019 clinical experiences and comfort levels with 20 recently approved agents","volume":"31","author":"Love","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","article-title":"A phase I trial of depsipeptide (FR901228) in patients with advanced cancer","volume":"2","author":"Marshall","year":"2002","journal-title":"J. Exp. Ther. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4161\/epi.3.3.6253","article-title":"A work in progress: the clinical development of histone deacetylase inhibitors","volume":"3","author":"Marsoni","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.0004","article-title":"Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous T-Cell lymphoma","author":"Martinez-Escala","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2340\/00015555-0789","article-title":"Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat","volume":"90","author":"Meyer","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0210","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1182\/blood-2011-09-379107","article-title":"Early CTCL diagnosis, a (miR)age no more","volume":"118","author":"Mishra","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0215","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-1715","article-title":"HDAC inhibitors and cardiac safety","volume":"13","author":"Molife","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0220","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428190290026367","article-title":"Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series","volume":"43","author":"Morgan","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0225","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. V.3.2016."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0230","series-title":"Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: non-Hodgkin lymphoma","author":"National Cancer Institute","year":"2016"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0235","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1345\/aph.1C510","article-title":"Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists","volume":"37","author":"Navari","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0240","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0245","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","article-title":"Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel","volume":"19","author":"Noonan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0250","unstructured":"ONTAK (denileukin diftitox) [package insert]. Woodcliff Lake, NJ : Eisai Inc., 2008."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0255","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0260","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0265","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1472-8206.2010.00835.x","article-title":"Mechanisms of hypokalemia-induced ventricular arrhythmogenicity","volume":"24","author":"Osadchii","year":"2010","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"70","key":"10.1016\/j.critrevonc.2016.07.001_bib0275","first-page":"573","article-title":"Treatment of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"18:566","author":"Parker","year":"2006","journal-title":"Dermatol. Nurs."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2010.06.012","article-title":"Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study","volume":"160","author":"Peacock","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0285","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0290","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0295","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0300","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase II trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0305","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/bjd.13849","article-title":"Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team","volume":"173","author":"Poligone","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2310\/7750.2009.08091","article-title":"Mycosis fungoides in the pediatric population: report from an international childhood registry of cutaneous lymphoma","volume":"14","author":"Pope","year":"2010","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0315","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0320","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0325","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfm730","article-title":"Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal","volume":"23","author":"Santoro","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0330","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2012.06.002","article-title":"Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review","volume":"85","author":"Schlaak","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0335","unstructured":"TARGRETIN (bexarotene) capsules [package insert]. Bridgewater, NJ : Valeant Pharmaceuticals Inc., 2013."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0340","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.07.001_bib0345","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0350","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/107327480100800213","article-title":"Infectious complications of cutaneous T-cell lymphoma","volume":"8","author":"Tsambiras","year":"2001","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0355","unstructured":"VALCHLOR (mechlorethamine HCl) 0.02% gel [prescribing information]. Malvern, PA: Ceptaris Therapeutics, Inc., 2012."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0360","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0365","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0370","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1359-6349(12)70010-1","article-title":"Major achievements of the EORTC cutaneous lymphoma task force (CLTF)","volume":"10","author":"Whittaker","year":"2012","journal-title":"EJC Suppl."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0375","unstructured":"ZOLINZA (vorinostat) [package insert]. Whitehouse Station, NJ : Merck & Co., 2015."},{"key":"10.1016\/j.critrevonc.2016.07.001_bib0380","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1067\/mjd.2002.124696","article-title":"Mycosis fungoides: the great imitator","volume":"47","author":"Zackheim","year":"2002","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T13:13:53Z","timestamp":1600866833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":76,"alternative-id":["S1040842816301561"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome): Use in a community setting","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}